Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

Granulomatosis with polyangiitis with breast involvement mimicking metastatic cancer: Case report and literature review.

Gadeyne L, Henckaerts L, Goffin KE, Gheysens O, Lerut E, Roskams T, Blockmans D, Floris G.

Eur J Rheumatol. 2019 Nov 25:1-3. doi: 10.5152/eurjrheum.2019.19065. [Epub ahead of print] Review.

PMID:
31782722
2.

Not Every Case of Temporal Arteritis Is Giant Cell Arteritis. Microscopic Polyangiitis Involving the Temporal Artery.

Planté-Bordeneuve T, Henckaerts L, Lerut E, Verbeken E, Blockmans D.

J Clin Rheumatol. 2018 Dec;24(8):440-442. doi: 10.1097/RHU.0000000000000670. Review. No abstract available.

PMID:
29293114
3.

Use of 18F-fluorodeoxyglucose positron emission tomography in the diagnosis of polymyalgia rheumatica-A prospective study of 99 patients.

Henckaerts L, Gheysens O, Vanderschueren S, Goffin K, Blockmans D.

Rheumatology (Oxford). 2018 Nov 1;57(11):1908-1916. doi: 10.1093/rheumatology/kex376.

PMID:
29136209
4.

Population-level analysis of gut microbiome variation.

Falony G, Joossens M, Vieira-Silva S, Wang J, Darzi Y, Faust K, Kurilshikov A, Bonder MJ, Valles-Colomer M, Vandeputte D, Tito RY, Chaffron S, Rymenans L, Verspecht C, De Sutter L, Lima-Mendez G, D'hoe K, Jonckheere K, Homola D, Garcia R, Tigchelaar EF, Eeckhaudt L, Fu J, Henckaerts L, Zhernakova A, Wijmenga C, Raes J.

Science. 2016 Apr 29;352(6285):560-4. doi: 10.1126/science.aad3503. Epub 2016 Apr 28.

5.

Outcome of patients with systemic diseases admitted to the medical intensive care unit of a tertiary referral hospital: a single-centre retrospective study.

Heijnen T, Wilmer A, Blockmans D, Henckaerts L.

Scand J Rheumatol. 2016;45(2):146-50. doi: 10.3109/03009742.2015.1067329. Epub 2015 Oct 8.

PMID:
26450794
6.

A tropical diabetic foot.

Henckaerts L, Naesens R, Vlieghe E, Jansens H, Gielen J, Ieven M, Moorkens G.

Acta Clin Belg. 2012 Sep-Oct;67(5):362-4.

PMID:
23189544
7.

Genetic variants in autophagy-related genes and granuloma formation in a cohort of surgically treated Crohn's disease patients.

Brinar M, Vermeire S, Cleynen I, Lemmens B, Sagaert X, Henckaerts L, Van Assche G, Geboes K, Rutgeerts P, De Hertogh G.

J Crohns Colitis. 2012 Feb;6(1):43-50. doi: 10.1016/j.crohns.2011.06.008. Epub 2011 Jul 16.

PMID:
22261526
8.

Long-term treatment of refractory invasive fungal infection with posaconazole: additive value of therapeutic drug monitoring.

Henckaerts L, Spriet I, Meersseman W, Peetermans WE.

Acta Clin Belg. 2011 May-Jun;66(3):231-2.

PMID:
21837936
9.

Malignancies and mortality in 200 patients with primary sclerosering cholangitis: a long-term single-centre study.

Fevery J, Henckaerts L, Van Oirbeek R, Vermeire S, Rutgeerts P, Nevens F, Van Steenbergen W.

Liver Int. 2012 Feb;32(2):214-22. doi: 10.1111/j.1478-3231.2011.02575.x. Epub 2011 Jul 5.

PMID:
21745316
10.

Effects of haptoglobin polymorphisms and deficiency on susceptibility to inflammatory bowel disease and on severity of murine colitis.

Márquez L, Shen C, Cleynen I, De Hertogh G, Van Steen K, Machiels K, Perrier C, Ballet V, Organe S, Ferrante M, Henckaerts L, Galicia G, Rutgeerts P, Ceuppens JL, Vermeire S.

Gut. 2012 Apr;61(4):528-34. doi: 10.1136/gut.2011.240978. Epub 2011 Jun 27.

PMID:
21708824
11.

Genetic variation in the autophagy gene ULK1 and risk of Crohn's disease.

Henckaerts L, Cleynen I, Brinar M, John JM, Van Steen K, Rutgeerts P, Vermeire S.

Inflamm Bowel Dis. 2011 Jun;17(6):1392-7. doi: 10.1002/ibd.21486. Epub 2010 Nov 28.

PMID:
21560199
12.

Three ulcerative colitis susceptibility loci are associated with primary sclerosing cholangitis and indicate a role for IL2, REL, and CARD9.

Janse M, Lamberts LE, Franke L, Raychaudhuri S, Ellinghaus E, Muri Boberg K, Melum E, Folseraas T, Schrumpf E, Bergquist A, Björnsson E, Fu J, Jan Westra H, Groen HJ, Fehrmann RS, Smolonska J, van den Berg LH, Ophoff RA, Porte RJ, Weismüller TJ, Wedemeyer J, Schramm C, Sterneck M, Günther R, Braun F, Vermeire S, Henckaerts L, Wijmenga C, Ponsioen CY, Schreiber S, Karlsen TH, Franke A, Weersma RK.

Hepatology. 2011 Jun;53(6):1977-85. doi: 10.1002/hep.24307. Epub 2011 May 2.

13.

Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci.

Melum E, Franke A, Schramm C, Weismüller TJ, Gotthardt DN, Offner FA, Juran BD, Laerdahl JK, Labi V, Björnsson E, Weersma RK, Henckaerts L, Teufel A, Rust C, Ellinghaus E, Balschun T, Boberg KM, Ellinghaus D, Bergquist A, Sauer P, Ryu E, Hov JR, Wedemeyer J, Lindkvist B, Wittig M, Porte RJ, Holm K, Gieger C, Wichmann HE, Stokkers P, Ponsioen CY, Runz H, Stiehl A, Wijmenga C, Sterneck M, Vermeire S, Beuers U, Villunger A, Schrumpf E, Lazaridis KN, Manns MP, Schreiber S, Karlsen TH.

Nat Genet. 2011 Jan;43(1):17-9. doi: 10.1038/ng.728. Epub 2010 Dec 12.

14.

Molecular reclassification of Crohn's disease by cluster analysis of genetic variants.

Cleynen I, Mahachie John JM, Henckaerts L, Van Moerkercke W, Rutgeerts P, Van Steen K, Vermeire S.

PLoS One. 2010 Sep 23;5(9):e12952. doi: 10.1371/journal.pone.0012952.

15.

Mutational characterization of the bile acid receptor TGR5 in primary sclerosing cholangitis.

Hov JR, Keitel V, Laerdahl JK, Spomer L, Ellinghaus E, ElSharawy A, Melum E, Boberg KM, Manke T, Balschun T, Schramm C, Bergquist A, Weismüller T, Gotthardt D, Rust C, Henckaerts L, Onnie CM, Weersma RK, Sterneck M, Teufel A, Runz H, Stiehl A, Ponsioen CY, Wijmenga C, Vatn MH; IBSEN Study Group, Stokkers PC, Vermeire S, Mathew CG, Lie BA, Beuers U, Manns MP, Schreiber S, Schrumpf E, Häussinger D, Franke A, Karlsen TH.

PLoS One. 2010 Aug 25;5(8):e12403. doi: 10.1371/journal.pone.0012403.

16.

Influence of the type of indigestible carbohydrate on plasma and urine short-chain fatty acid profiles in healthy human volunteers.

Verbeke K, Ferchaud-Roucher V, Preston T, Small AC, Henckaerts L, Krempf M, Wang H, Vonk RJ, Priebe MG.

Eur J Clin Nutr. 2010 Jul;64(7):678-84. doi: 10.1038/ejcn.2010.92. Epub 2010 May 26.

PMID:
20502475
17.

Genome-wide association analysis in primary sclerosing cholangitis.

Karlsen TH, Franke A, Melum E, Kaser A, Hov JR, Balschun T, Lie BA, Bergquist A, Schramm C, Weismüller TJ, Gotthardt D, Rust C, Philipp EE, Fritz T, Henckaerts L, Weersma RK, Stokkers P, Ponsioen CY, Wijmenga C, Sterneck M, Nothnagel M, Hampe J, Teufel A, Runz H, Rosenstiel P, Stiehl A, Vermeire S, Beuers U, Manns MP, Schrumpf E, Boberg KM, Schreiber S.

Gastroenterology. 2010 Mar;138(3):1102-11. doi: 10.1053/j.gastro.2009.11.046. Epub 2009 Nov 26.

PMID:
19944697
18.

Transmission ratio distortion of DLG5 R30Q: evidence for prenatal selection?

Henckaerts L, Vlietinck R, Derom C, Boonen S, Rutgeerts P, Vermeire S.

Inflamm Bowel Dis. 2010 Jun;16(6):910-1. doi: 10.1002/ibd.21109. No abstract available.

PMID:
19774648
19.

Genetic risk profiling and prediction of disease course in Crohn's disease patients.

Henckaerts L, Van Steen K, Verstreken I, Cleynen I, Franke A, Schreiber S, Rutgeerts P, Vermeire S.

Clin Gastroenterol Hepatol. 2009 Sep;7(9):972-980.e2. doi: 10.1016/j.cgh.2009.05.001. Epub 2009 May 5.

PMID:
19422935
20.

Confirmation of multiple Crohn's disease susceptibility loci in a large Dutch-Belgian cohort.

Weersma RK, Stokkers PC, Cleynen I, Wolfkamp SC, Henckaerts L, Schreiber S, Dijkstra G, Franke A, Nolte IM, Rutgeerts P, Wijmenga C, Vermeire S.

Am J Gastroenterol. 2009 Mar;104(3):630-8. doi: 10.1038/ajg.2008.112. Epub 2009 Jan 27.

PMID:
19174780
21.

Polymorphisms in innate immunity genes predispose to bacteremia and death in the medical intensive care unit.

Henckaerts L, Nielsen KR, Steffensen R, Van Steen K, Mathieu C, Giulietti A, Wouters PJ, Milants I, Vanhorebeek I, Langouche L, Vermeire S, Rutgeerts P, Thiel S, Wilmer A, Hansen TK, Van den Berghe G.

Crit Care Med. 2009 Jan;37(1):192-201, e1-3. doi: 10.1097/CCM.0b013e31819263d8.

PMID:
19050632
22.

Cystic fibrosis transmembrane conductance regulator gene polymorphisms in patients with primary sclerosing cholangitis.

Henckaerts L, Jaspers M, Van Steenbergen W, Vliegen L, Fevery J, Nuytten H, Roskams T, Rutgeerts P, Cassiman JJ, Vermeire S, Cuppens H.

J Hepatol. 2009 Jan;50(1):150-7. doi: 10.1016/j.jhep.2008.07.033. Epub 2008 Oct 7.

PMID:
18992954
23.

Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study.

Fidder H, Schnitzler F, Ferrante M, Noman M, Katsanos K, Segaert S, Henckaerts L, Van Assche G, Vermeire S, Rutgeerts P.

Gut. 2009 Apr;58(4):501-8. doi: 10.1136/gut.2008.163642. Epub 2008 Oct 2.

PMID:
18832524
24.

Clustering of (auto)immune diseases with early-onset and complicated inflammatory bowel disease.

Bueno de Mesquita M, Ferrante M, Henckaerts L, Joossens M, Janssens V, Hlavaty T, Pierik M, Joossens S, Van Schuerbeek N, Van Assche G, Rutgeerts P, Vermeire S, Hoffman I.

Eur J Pediatr. 2009 May;168(5):575-83. doi: 10.1007/s00431-008-0798-7. Epub 2008 Aug 1.

PMID:
18670786
25.

The role of genetics in inflammatory bowel disease.

Henckaerts L, Figueroa C, Vermeire S, Sans M.

Curr Drug Targets. 2008 May;9(5):361-8. Review.

PMID:
18473763
26.

The Crohn's disease susceptibility gene DLG5 as a member of the CARD interaction network.

Friedrichs F, Henckaerts L, Vermeire S, Kucharzik T, Seehafer T, Möller-Krull M, Bornberg-Bauer E, Stoll M, Weiner J 3rd.

J Mol Med (Berl). 2008 Apr;86(4):423-32. doi: 10.1007/s00109-008-0307-5. Epub 2008 Mar 12.

PMID:
18335190
27.

Intravenous iron therapy restores functional iron deficiency induced by infliximab.

Katsanos K, Cavalier E, Ferrante M, Van Hauwaert V, Henckaerts L, Schnitzler F, Katsaraki A, Noman M, Vermeire S, Tsianos EV, Rutgeerts P, Chapelle JP, Van Assche G.

J Crohns Colitis. 2007 Dec;1(2):97-105. doi: 10.1016/j.crohns.2007.08.005. Epub 2007 Sep 27.

28.

Gender-stratified analysis of DLG5 R30Q in 4707 patients with Crohn disease and 4973 controls from 12 Caucasian cohorts.

Browning BL, Annese V, Barclay ML, Bingham SA, Brand S, Büning C, Castro M, Cucchiara S, Dallapiccola B, Drummond H, Ferguson LR, Ferraris A, Fisher SA, Gearry RB, Glas J, Henckaerts L, Huebner C, Knafelz D, Lakatos L, Lakatos PL, Latiano A, Liu X, Mathew C, Müller-Myhsok B, Newman WG, Nimmo ER, Noble CL, Palmieri O, Parkes M, Petermann I, Rutgeerts P, Satsangi J, Shelling AN, Siminovitch KA, Török HP, Tremelling M, Vermeire S, Valvano MR, Witt H.

J Med Genet. 2008 Jan;45(1):36-42. Epub 2007 Aug 10.

PMID:
17693570
29.

Mutations in pattern recognition receptor genes modulate seroreactivity to microbial antigens in patients with inflammatory bowel disease.

Henckaerts L, Pierik M, Joossens M, Ferrante M, Rutgeerts P, Vermeire S.

Gut. 2007 Nov;56(11):1536-42. Epub 2007 Jun 26.

30.

The RANTES -28 g polymorphism is associated with primary sclerosing cholangitis.

Henckaerts L, Fevery J, Van Steenbergen W, Verslype C, Nevens F, Yap P, Roskams T, Rutgeerts P, Vermeire S.

Gut. 2007 Jun;56(6):891-2. No abstract available.

31.

New serological markers in inflammatory bowel disease are associated with complicated disease behaviour.

Ferrante M, Henckaerts L, Joossens M, Pierik M, Joossens S, Dotan N, Norman GL, Altstock RT, Van Steen K, Rutgeerts P, Van Assche G, Vermeire S.

Gut. 2007 Oct;56(10):1394-403. Epub 2007 Apr 24.

32.

Predictive model for the outcome of infliximab therapy in Crohn's disease based on apoptotic pharmacogenetic index and clinical predictors.

Hlavaty T, Ferrante M, Henckaerts L, Pierik M, Rutgeerts P, Vermeire S.

Inflamm Bowel Dis. 2007 Apr;13(4):372-9.

PMID:
17206723
33.

NOD2/CARD15 disease associations other than Crohn's disease.

Henckaerts L, Vermeire S.

Inflamm Bowel Dis. 2007 Feb;13(2):235-41. Review.

PMID:
17206682
34.

CT and MR imaging of gastrointestinal tuberculosis.

De Backer AI, Mortelé KJ, De Keulenaer BL, Henckaerts L, Verhaert L.

JBR-BTR. 2006 Jul-Aug;89(4):190-4.

PMID:
16999319
35.

The role of vascular endothelial growth factor (VEGF) in inflammatory bowel disease.

Ferrante M, Pierik M, Henckaerts L, Joossens M, Claes K, Van Schuerbeek N, Vlietinck R, Rutgeerts P, Van Assche G, Vermeire S.

Inflamm Bowel Dis. 2006 Sep;12(9):870-8.

PMID:
16954806
36.

CC-type chemokine receptor 5-Delta32 mutation protects against primary sclerosing cholangitis.

Henckaerts L, Fevery J, Van Steenbergen W, Verslype C, Yap P, Nevens F, Roskams T, Libbrecht L, Rutgeerts P, Vermeire S.

Inflamm Bowel Dis. 2006 Apr;12(4):272-7.

PMID:
16633049
37.

Association of organic cation transporter risk haplotype with perianal penetrating Crohn's disease but not with susceptibility to IBD.

Vermeire S, Pierik M, Hlavaty T, Claessens G, van Schuerbeeck N, Joossens S, Ferrante M, Henckaerts L, Bueno de Mesquita M, Vlietinck R, Rutgeerts P.

Gastroenterology. 2005 Dec;129(6):1845-53.

PMID:
16344053
38.

Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease.

Hlavaty T, Pierik M, Henckaerts L, Ferrante M, Joossens S, van Schuerbeek N, Noman M, Rutgeerts P, Vermeire S.

Aliment Pharmacol Ther. 2005 Oct 1;22(7):613-26.

Supplemental Content

Loading ...
Support Center